The Federal Competition Commission (CFC) has announced that it is barring Nestle SA from buying Pfizer Inc’d infant formula arm in Mexico, citing competition concerns. The deal would have been made for $11.85 billion, as Nestle outbid Groupe Danone SA last April to buy the infant formula business. The CFC determined that the eventual 71 percent stake in the sector for stage one and two formula, and an 88 percent stake for stage three formula, would be too much of a dominant position for Nestle. The CFC used quantitative techniques to come to its conclusion.
Featured News
El Al Accused of Denying Rival Hangar Access Amid Gaza War
Feb 23, 2026 by
CPI
Live Nation Seeks to Delay Antitrust Trial to Pursue Appeal
Feb 23, 2026 by
CPI
Government Auditors Outline Dramatic CFPB Downsizing in New Congressional Report
Feb 23, 2026 by
CPI
UK Nominates Doug Gurr to Lead Competition Watchdog for Full Term
Feb 23, 2026 by
CPI
DOJ Clears Getty Images–Shutterstock Merger Without Conditions
Feb 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece